Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  Xing Huang,et al.  NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1 , 2021, Nature Communications.

[3]  Huidong Shi,et al.  WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape , 2021, Journal for ImmunoTherapy of Cancer.

[4]  G. Kinker,et al.  B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication , 2021, Frontiers in Cell and Developmental Biology.

[5]  P. Singh,et al.  Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer , 2021, Cancer Research.

[6]  A. Vazquez,et al.  Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells , 2021, Molecular cell.

[7]  R. Kalluri,et al.  Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. , 2021, Cancer cell.

[8]  Minhua Liang,et al.  Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[9]  Qiaofei Liu,et al.  Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming , 2021, Frontiers in Cell and Developmental Biology.

[10]  Felicia L. Lenzo,et al.  Immune profiling and immunotherapeutic targets in pancreatic cancer , 2021, Annals of translational medicine.

[11]  Yinmo Yang,et al.  Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression , 2020, EBioMedicine.

[12]  B. Garcia,et al.  Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. , 2020, Cancer discovery.

[13]  M. Ohh,et al.  PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells , 2020, Journal of experimental & clinical cancer research : CR.

[14]  Jessica S. Yu,et al.  Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer , 2020, Nature Cancer.

[15]  G. Lesinski,et al.  Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer , 2020, Molecular Cancer Therapeutics.

[16]  A. Maitra,et al.  Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer , 2020, The Journal of experimental medicine.

[17]  G. Kroemer,et al.  CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer , 2020, Gut.

[18]  B. Tycko,et al.  A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer , 2020, Cancer Research.

[19]  T. Putoczki,et al.  Emerging roles for the IL-6 family of cytokines in pancreatic cancer , 2020, Clinical science.

[20]  S. M. Toor,et al.  Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression , 2020, Frontiers in Immunology.

[21]  R. Jiang,et al.  IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma , 2020, Journal for immunotherapy of cancer.

[22]  Z. Yao,et al.  Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity , 2020, Journal for immunotherapy of cancer.

[23]  Jiayu Zhang,et al.  PD-L1 expression increased by IFN-γ via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer , 2020, Oncology letters.

[24]  D. Nowis,et al.  Myeloid Cell-Derived Arginase in Cancer Immune Response , 2020, Frontiers in Immunology.

[25]  Xunbin Wei,et al.  PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC , 2020, Signal Transduction and Targeted Therapy.

[26]  J. Bowser,et al.  CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers , 2020, Frontiers in Immunology.

[27]  Alexander H. E. Morrison,et al.  Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity , 2020, Proceedings of the National Academy of Sciences.

[28]  A. Maitra,et al.  Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. , 2020, Gastroenterology.

[29]  D. Bar-Sagi,et al.  Tumor Cell-Derived IL-1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. , 2020, Cancer research.

[30]  Michelle A. Anderson,et al.  Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. , 2020, Cancer discovery.

[31]  Jun Zhang,et al.  Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity , 2020, Theranostics.

[32]  P. Timpson,et al.  Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. , 2019, Cancer letters.

[33]  Ying Zhou,et al.  Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. , 2019, Life sciences.

[34]  B. Durden,et al.  Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. , 2019, The Journal of clinical investigation.

[35]  A. Adler,et al.  IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors , 2019, Journal of Immunotherapy for Cancer.

[36]  Kongming Wu,et al.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.

[37]  Arash Salmaninejad,et al.  PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy , 2019, Journal of cellular physiology.

[38]  S. Baylin,et al.  The emerging role of epigenetic therapeutics in immuno-oncology , 2019, Nature Reviews Clinical Oncology.

[39]  S. Meierjohann,et al.  IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression , 2019, Journal of Experimental & Clinical Cancer Research.

[40]  Xing Huang,et al.  USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity , 2019, Cancer Immunology Research.

[41]  G. Hortobagyi,et al.  Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. , 2019, Cancer cell.

[42]  T. Lawrence,et al.  Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. , 2019, Cancer research.

[43]  Y. Maehara,et al.  IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. , 2019, The Journal of surgical research.

[44]  S. Sze,et al.  Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift , 2019, Oncogene.

[45]  P. Fan,et al.  HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[46]  Sanjay Gupta,et al.  Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer , 2019, Nature Communications.

[47]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[48]  P. Fan,et al.  Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer , 2019, Journal of experimental & clinical cancer research : CR.

[49]  R. Alemany,et al.  IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1 , 2019, The Journal of Immunology.

[50]  P. A. Harris,et al.  RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. , 2018, Cancer cell.

[51]  Y. Chu,et al.  The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy , 2018, Journal of Neuroinflammation.

[52]  Y. Morine,et al.  Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction , 2018, Cell Communication and Signaling.

[53]  R. Sun,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[54]  C. Iacobuzio-Donahue,et al.  Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases , 2017, Science.

[55]  Chen Huang,et al.  Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. , 2018, Cancer research.

[56]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[57]  W. Birchmeier,et al.  Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. , 2018, Cell reports.

[58]  R. Qin,et al.  Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway , 2017, Oncotarget.

[59]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[60]  Jinyan Wang,et al.  CD25‐expressing Th17 cells mediate CD8+ T cell suppression in CTLA‐4 dependent mechanisms in pancreatic ductal adenocarcinoma , 2017, Experimental cell research.

[61]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[62]  L. Dyck,et al.  Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors , 2017, Front. Immunol..

[63]  F. McAllister,et al.  CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer , 2017, Cancer Immunology, Immunotherapy.

[64]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[65]  D. Bar-Sagi,et al.  Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer , 2017, Cell reports.

[66]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[67]  Huidong Shi,et al.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion , 2017, Journal of the National Cancer Institute.

[68]  H. Horita,et al.  Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton , 2017, Neoplasia.

[69]  P. Blackshear,et al.  Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA , 2017, Immunity.

[70]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[71]  B. Stanger,et al.  Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer , 2016, Clinical Cancer Research.

[72]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[73]  R. Houot,et al.  Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? , 2016, European journal of cancer.

[74]  Michael C. Ostrowski,et al.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer , 2016, Gut.

[75]  A. Maitra,et al.  Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma , 2016, Scientific Reports.

[76]  B. Stanger,et al.  Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. , 2016, JCI insight.

[77]  N. Merchant,et al.  Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells , 2016, Oncotarget.

[78]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[79]  M. Pasca di Magliano,et al.  Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer , 2016, Gut.

[80]  R. Vonderheide,et al.  CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. , 2016, Cell reports.

[81]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[82]  M. Stein,et al.  Targeting tumor-associated macrophages to combat pancreatic cancer , 2016, Oncotarget.

[83]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[84]  J. Connolly,et al.  TLR7 and TLR9 ligands regulate antigen presentation by macrophages. , 2016, International immunology.

[85]  A. Ohta.  A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment , 2016, Front. Immunol..

[86]  R. Gillies,et al.  Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. , 2016, Cancer research.

[87]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[88]  C. Clendenin,et al.  Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. , 2015, Gastroenterology.

[89]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[90]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[91]  E. Jaffee,et al.  Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells , 2015, Cancer Immunology Research.

[92]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[93]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[94]  A. Descoteaux,et al.  Macrophage Cytokines: Involvement in Immunity and Infectious Diseases , 2014, Front. Immunol..

[95]  Hidde L. Ploegh,et al.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.

[96]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[97]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[98]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[99]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[100]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[101]  Paul A. Bowles,et al.  Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. , 2014, Molecular immunology.

[102]  Teruhiko Yoshida,et al.  Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer , 2014, Cancer science.

[103]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[104]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[105]  B. Zetter,et al.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. , 2013, Cancer research.

[106]  L. Walker.  Treg and CTLA-4: Two intertwining pathways to immune tolerance , 2013, Journal of autoimmunity.

[107]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[108]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[109]  Y. Kanai,et al.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.

[110]  A. Tolcher,et al.  Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors , 2013, Oncoimmunology.

[111]  K. Olive,et al.  Genetically engineered mouse models of pancreatic cancer. , 2012, Cancer journal.

[112]  G. V. D. Windt,et al.  Metabolic switching and fuel choice during T‐cell differentiation and memory development , 2012, Immunological reviews.

[113]  Bin Hu,et al.  Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation , 2012, International journal of cancer.

[114]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[115]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[116]  L. Varani,et al.  HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.

[117]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[118]  M. Fresno,et al.  Prostaglandin E2 and T cells: friends or foes? , 2011, Immunology and cell biology.

[119]  T. Wynn,et al.  Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase , 2011, The Journal of Immunology.

[120]  L. Zitvogel,et al.  IL-18 induces PD-1-dependent immunosuppression in cancer. , 2011, Cancer research.

[121]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[122]  T. Bukowski,et al.  Vstm3 is a member of the CD28 family and an important modulator of T‐cell function , 2011, European journal of immunology.

[123]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[124]  A. Siriwardena,et al.  Epidermal Growth Factor Receptor in Pancreatic Cancer , 2011, Cancers.

[125]  Douglas B. Evans,et al.  High Levels of Expression of Human Stromal Cell–Derived Factor-1 Are Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[126]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[127]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[128]  T. Padhya,et al.  Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.

[129]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[130]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[131]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[132]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[133]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[134]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[136]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[137]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[138]  S. Morris,et al.  Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. , 2005, Gene.

[139]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[140]  J. Yates,et al.  Differential expression of CTLA‐4 among T cell subsets , 2004, Clinical and experimental immunology.

[141]  In-Jeong Kim,et al.  Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1 , 2004, The Journal of Immunology.

[142]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[143]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[144]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[145]  S. Colgan,et al.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.

[146]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[147]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[148]  L. Ignarro,et al.  IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. , 2000, American journal of physiology. Cell physiology.

[149]  B. Seliger,et al.  Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin , 2000, Bone Marrow Transplantation.

[150]  G. Le Gros,et al.  The role of CTLA‐4 in the regulation of T cell immune responses , 1999, Immunology and cell biology.

[151]  B. Seliger,et al.  Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes , 1996, Scandinavian journal of immunology.

[152]  F. Guadagni,et al.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[153]  W D Holder,et al.  The nude mouse as a model for the study of human pancreatic cancer. , 1989, The Journal of surgical research.

[154]  F. Burnet.  Immunological Surveillance in Neoplasia , 1971, Transplantation reviews.

[155]  P. A. van der Merwe,et al.  Lck and the nature of the T cell receptor trigger. , 2011, Trends in immunology.

[156]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[157]  M. H. Tan,et al.  Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. , 1985, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.